By Colin Kellaher

Johnson & Johnson's Janssen Pharmaceutical Cos. unit on Monday said it has filed with the European Medicines Agency seeking approval of teclistamab for the treatment of patients with relapsed or refractory multiple myeloma.

The drugmaker said the filing is supported by data from an open-label, multicenter clinical trial evaluating the safety and efficacy of teclistamab in adults with the incurable blood cancer.

Janssen last month reported data from the study that showed continued deep and durable responses of teclistamab in heavily pretreated patients, and the company subsequently filed for U.S. Food and Drug Administration approval of teclistamab.

Janssen is currently studying teclistamab, an off-the-shelf T-cell investigational redirecting bispecific antibody, in several monotherapy and combination studies.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

January 31, 2022 08:23 ET (13:23 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Johnson and Johnson Charts.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Johnson and Johnson Charts.